Entries |
Document | Title | Date |
20080214531 | Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipdemia - Methods for the treatment of insulin resistance, diabetes, and/or diabetes associated dyslipidemia by administering niacin and meloxicam are disclosed. | 09-04-2008 |
20080255104 | Nsaid Compositions - The invention is directed to a composition and method for treating acute pain using a composition comprising one or more NSAID's, a metasilicate and optionally a fatty acid ester resulting in increased absorption of poorly soluble active NSAID's and increased absorption in suppressed vagal systems. The preferred composition comprises meloxicam on a metasilicate matrix; and one or more of the following: sodium bicarbonate, Gelucire®, and tartaric acid. | 10-16-2008 |
20080293703 | Topical Preparation and Method for Transdermal Delivery and Localization of Therapeutic Agents - Disclosed herein is a preparation for topically delivering and localizing therapeutic agents, comprising: a vasoconstrictor for retarding vascular dispersion of a therapeutic agent; and a penetration enhancer for facilitating penetration of the vasoconstrictor and the therapeutic agent through a patient's skin. Further disclosed is an associated method of topically delivering and localizing therapeutic agents, comprising the steps of: using a vasoconstrictor for retarding vascular dispersion of a therapeutic agent; in combination with using a penetration enhancer for facilitating penetration of the vasoconstrictor and the therapeutic agent through a patient's skin. Also disclosed are various courses of treatment, which comprise applying the various disclosed combinations of agents to the patient's skin. | 11-27-2008 |
20090018121 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR RHEUMATOID ARTHRITIS - The present invention relates to a preventive and/or therapeutic agent for rheumatoid arthritis. The present invention provides a preventive and/or therapeutic agent for rheumatoid arthritis containing 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one and a COX2 inhibitor. | 01-15-2009 |
20090075985 | ARYL SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE - Aryl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula | 03-19-2009 |
20090143368 | Use of Cinnamoyl Compound - A composition for inhibiting the extracellular matrix gene transcription comprising a cinnamoyl compound represented by the formula (I): | 06-04-2009 |
20090186883 | Stable Aqueous Suspension - An aqueous pharmaceutical suspension comprising: (i) at least one non-steroidal anti-inflammatory drug; (ii) an aqueous buffer system; (iii) xanthan gum; (iv) polyvinyl pyrrolidone; and (v) glycerol wherein the suspension is free from pregelatinised starch, amino polycarboxylic acid, microcrystalline cellulose, hydroxypropylmethyl cellulose, polyoxyethylene sorbitan monooleate, silicon dioxide and taste modifying agents selected from the group consisting of bulk sweeteners, intense sweeteners, flavouring agents and mixtures thereof. | 07-23-2009 |
20090197874 | SOLID FORMS CONTAINING MELOXICAM WITH IMPROVED BUCCAL TASTE AND PROCESS FOR THEIR PREPARATION - A solid dosage form of meloxicam containing an acid and sugars or polyalcohols or a mixture thereof. | 08-06-2009 |
20090203680 | In vivo studies of crystalline forms of meloxicam - The invention is directed to novel crystalline forms of meloxicam. These novel crystalline forms of meloxicam have improved bioavailability, an enhanced rate of dissolution and shorter time to C | 08-13-2009 |
20090215757 | Process for Preparation of High-Purity Meloxicam and Meloxicam Potassium Salt - The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium salt monohydrate is produced. Said salt is subsequently treated with mineral or organic acid to yield high-purity meloxicam. | 08-27-2009 |
20090221563 | ORAL SUSPENSION COMPRISING MELOXICAM - The present invention relates to an oral suspension comprising meloxicam, its preparation and its use in alleviating inflammation and pain in both acute and chronic musculo-skeletal disorders. | 09-03-2009 |
20090239852 | USE OF OXICAM COMPOUNDS - Methods of treating and/or preventing arteriosclerosis are disclosed. In certain methods, a composition containing at least one lornoxicam or lornoxicam analogue that inhibits cyclooxygenase 1 and cyclooxygenase 2 (COX 1 and COX 2), cannot cross the blood/brain barrier under physiological conditions, and reduces the prostaglandin E2-induced induction of the amyloid precursor protein (APP) is administered to a subject to treat and/or prevent arteriosclerosis in the subject. | 09-24-2009 |
20090281093 | ANTI-INFLAMMATORY COMPOUNDS - The present invention relates to novel non steroidal anti-inflammatory compounds (NSAIDs) that release hydrogen sulfide (H | 11-12-2009 |
20090306058 | Sulphone Derivatives for Treatment of Cancer - Compounds of Formula (I) are disclosed for treatment of cancer. | 12-10-2009 |
20090325943 | VETERINARY PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND INFLAMMATION - This invention relates to veterinary pharmaceutical compositions based on a combination of tramadol and meloxicam or carprofen for the treatment of pain and inflammation in animals. | 12-31-2009 |
20100004231 | INHIBITORS OF BURTON'S TYROSINE KINASE - This application discloses 5-phenyl-1H-pyrazin-2-one derivatives according to generic Formulae I-V: | 01-07-2010 |
20100009977 | Process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1- ,2-thiazine-6-sulfonamide-1,1-dioxide. - Disclosed herein is an improved process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide (Brinzolamide) and novel intermediates thereof. | 01-14-2010 |
20100035868 | METHODS OF TREATMENT OF UTERINE PATHOLOGICAL CONDITIONS - A method of treating or preventing a pathological condition of the uterus in an individual the method comprising administering to the individual any one or more of an inhibitor of cyclooxygenase-2 (COX-2), an inhibitor of prostaglandin E synthase (PGES), or an EP2 or EP4 receptor antagonist. Typically, the pathological condition is uterine cancer, fibroids or endometriosis. | 02-11-2010 |
20100063035 | CARBONIC ANHYDRASE INHIBITORS DERIVATIVES - Nitroderivatives of dorzolamide and brinzolamide having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma, ocular hypertension, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, hypertensive retinopathy and retinal vasculopathies. | 03-11-2010 |
20100081652 | Cinnamoyl Compound and Use Thereof - Disclosed is an extracellular matrix genetranscription inhibitor composition or the like characterized by containing a cinnamoyl compound represented by the formula (I) below: | 04-01-2010 |
20100093711 | ORGANIC COMPOUNDS - The present invention provides a compound of formula I: | 04-15-2010 |
20100093712 | TWO-COMPONENT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PAIN - The present invention is directed to a pharmaceutical composition that includes a combination of about 2-5 milligrams of a non-steroidal anti-inflammatory drug and from about 2-30 milligrams of an opioid analgesic in a single pharmaceutical dosage unit that can provide effective chronic pain management with the added benefit of reduced side effects such as withdrawal and gastrointestinal disorders. The non-steroidal anti-inflammatory drug may be piroxicam and the opioid analgesic may be buprenorphine. The present invention also provides for a method of managing pain in a patient that includes administering the pharmaceutical composition previously described. The pharmaceutical composition previously described may be administered in a single or multiple dosage regimen. | 04-15-2010 |
20100125067 | SULFONAMIDE INHIBITORS OF CARBONIC ANHYDRASE II - The present invention relates to new sulfonamide inhibitors of carbonic anhydrase II, pharmaceutical compositions thereof, and methods of use thereof. | 05-20-2010 |
20100137292 | Pharmaceutical formulations of meloxicam - This invention is a novel pharmaceutical formulation of aqueous EDTA (Ethylene diamine tetraacetic acid) free solution of meloxicam in combination with meglumin for administration by oral or parenteral route, comprising one or more pharmaceutically acceptable excipients which is comprising N,N dimethylacetamide and propylene glycol for treating mammals, preferably animals. | 06-03-2010 |
20100144719 | PHARMACEUTICAL SUSPENSION - The present invention is directed to the provision of a pharmaceutical suspension. The suspension includes high molecular weight polyethylene glycol as a suspending agent. The suspension also typically includes an antimicrobial agent (e.g., polymeric quaternary ammonium compound), an antimicrobial system (e.g., borate/polyol complex system) or both. The suspension has been found particularly useful as an ophthalmic suspension, but can be used in other instances as well. | 06-10-2010 |
20100152173 | Tablet Having Improved Stability With At Least Two Actives - The present invention relates to a tablet comprising at least a first and second active, the first active being in the form of a non-aqueous granulate, the second active ingredient being in the form of melt extrudated granules or a granulate (aqueous or non-aqueous). The first and second active forms are blended together. The present invention is further directed to a method of producing said tablet. | 06-17-2010 |
20100227854 | Oral Pharmaceutical Formulations Containing Non-Steroidal Anti-Inflammatory Drugs and Acid Inhibitors - The present disclosure provides enteric coated capsules and orally dissolving films comprising non-steroidal anti-inflammatory drugs and acid inhibitors, as well as methods of treating treatment humans for pain and/or inflammation while reducing gastrointestinal side effects. | 09-09-2010 |
20100267705 | PHARMACEUTICAL FORMULATION CONTAINING LIPOPHILIC DRUGS AND MILK AS A SOLUBILIZING/DISPENSING AGENT AND METHOD FOR THE PREPARATION THEREOF - The present invention relates to an improved pharmaceutical composition and in particular to a pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of a lipophilic active ingredient with milk as a solubilizing/dispersing agent and methods for the preparation thereof. | 10-21-2010 |
20100280017 | Combination of Selected Analgesics and Cox-II Inhibitors - Combinations of certain analgesics with COX-II inhibitors, related pharmaceutical compositions, including advantageous galenical forms containing these combinations, and the use of such combinations in methods of treatment, in particular for the treatment of pain. | 11-04-2010 |
20100292225 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS - The present invention provides a compound of formula I; | 11-18-2010 |
20100317655 | SULFONAMIDE INHIBITORS OF CARBONIC ANHYDRASE - The present invention relates to new sulfonamide inhibitors of carbonic anhydrase activity, pharmaceutical compositions thereof, and methods of use thereof. | 12-16-2010 |
20100324031 | AQUEOUS PHARMACEUTICAL COMPOSITIONS CONTAINING BORATE-POLYOL COMPLEXES - The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include at two different polyols in conjunction with borate and a low concentration of benzalkonium chloride. | 12-23-2010 |
20110028460 | TOPICAL FORMULATION - It has been discovered that certain combinations compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of active agents. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. There is described herein a topical formulation comprising (i) at least one active agent; (ii) a first compound, and (iii) a second compound, wherein the first compound and second compound are different, and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate. | 02-03-2011 |
20110034448 | CARBONIC ANHYDRASE INHIBITOR SUSTAINED RELEASE INTRAOCULAR DRUG DELIVERY SYSTEMS - Biocompatible intraocular drug delivery systems include a carbonic anhydrase inhibitor therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others. | 02-10-2011 |
20110086847 | THIADIAZOLE MODULATORS OF BETA ADRENERGIC RECEPTOR - The present invention relates to new thiadiazole modulators of beta adrenergic receptor activity, pharmaceutical compositions thereof, and methods of use thereof. | 04-14-2011 |
20110098284 | Methods and compositions for treating pain - The present invention provides a method of treating or preventing pain, inflammation or fever comprising administering to a subject in need of such treatment or prevention a therapeutically effective amount of one or more selected NSAIDs, in racemic, enantiomeric excess, or enantiomeric form, in combination with ethylenediamine and/or piperazine. | 04-28-2011 |
20110105479 | Inhibitors of Bruton's Tyrosine Kinase - This application discloses 5-phenyl-1H-pyridin-2-one and 6-phenyl-2H-pyridazin-3-one derivatives according to generic Formulae I-IV: | 05-05-2011 |
20110105480 | PHARMACEUTICAL TRANSDERMAL COMPOSITIONS AND METHOD FOR TREATING INFLAMMATION IN CATTLE - Novel transdermal preparations combining a non-steroidal anti-inflammatory drug (NSAID) selected from groups such as oxicams (for example, meloxicam), propionic acids (for example, ketoprofen) and anthranilic acids (for example, tolfenamic acid), are disclosed. Methods for using and administering such preparation in the treatment of inflammatory conditions in bovines are also disclosed. | 05-05-2011 |
20110118243 | ANTI-INFLAMMATORY DRUG DELIVERY SYSTEM - The invention provides dosage forms for the delivery of one or more non-steroidal anti-inflammatory drugs to equines. The dosage forms are palatable, desirable, and easy to administer with little or no mess or waste. The dosage form can be a cookie that includes one or more grain products, one or more protein products, one or more flavoring agents, or a combination thereof. The dosage form also includes a therapeutically effective amount of one or more non-steroidal anti-inflammatory drugs, for example, for the treatment of joint deterioration, swelling and inflammation, founder, fever, laminitis, or a combination thereof. The drug can be phenylbutazone or firocoxib and the dosage unit can be conveniently hand-fed to the horse. | 05-19-2011 |
20110160194 | Anti-Inflammatory Analgesic External Preparation - An external preparation that effectively produces the anti-inflammatory analgesic effect of a non-steroidal anti-inflammatory analgesic agent, and reduces skin irritation on the application site of the preparation and has an excellent effect on pain associated with inflammation such as chronic rheumatoid arthritis, osteoarthritis, and also lumbago is provided. The external preparation includes a non-steroidal anti-inflammatory analgesic agent and oxybuprocaine or a pharmaceutically acceptable salt thereof. The external preparation includes the non-steroidal anti-inflammatory analgesic agent at a content of 0.1 to 10 wt % based on the total weight of the formulation and oxybuprocaine or a pharmaceutically acceptable salt thereof at a content of 0.01 to 60 wt % based on the total weight of the formulation. The external preparation has a dosage form as an external preparation wherein the dosage form is an ointment, a solution, a suspension, an emulsion, a lotion, a cataplasm, a tape, an aerosol, or a powder for external use. | 06-30-2011 |
20110212948 | TREATMENT OF NEONATE FOALS WITH MELOXICAM - A method of administering meloxicam containing compositions to neonate foals of 6 weeks of age or less is provided. The inventors have discovered that foals of 6 weeks of age or less can have meloxicam administered at a dosage of 0.6 mg/kg without any negative or adverse reaction by the foal. The method also provides a dosing regimen for obtaining first peak plasma concentrations of approximately 800 ng/ml, average plasma concentration levels of 200 ng/ml for 6 hours after a single dose, and sustained plasma concentration levels of 100 ng/ml with twice daily dosing. | 09-01-2011 |
20110218191 | USE OF MELOXICAM FOR THE LONG TERM-TREATMENT OF KIDNEY DISORDERS IN CATS - The invention is directed to a formulation containing NSAIDs or a pharmacologically acceptable salt thereof of and one or more vehicles for the treatment of kidney diseases in cats. Serum creatinine concentrations increase less over time following treatment with NSAID compared to untreated cats. | 09-08-2011 |
20110224196 | TREATMENT OF OBSTRUCTIVE SLEEP APNEA SYNDROME WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ADDITIONAL ACTIVE AGENT - This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from obstructive sleep apnea syndrome (OSAS). Treatment of OSAS is effected by administering a carbonic anhydrase inhibitor to the patient in combination with at least one additional active agent. Examples of additional active agents include modafinil, eszopiclone, zolpidem, zaleplon, and phentermine. | 09-15-2011 |
20110263580 | METHOD FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS - This invention relates to a method for treating or preventing diseases associated with the deposition of β-amyloid peptide in the brain, such as Alzheimer's disease, said method involving administration of a gamma-secretase inhibitor in an intermittent dosing regime to a patient in need thereof. | 10-27-2011 |
20110275617 | OPHTHALMIC COMPOSITION - The present invention provides an ophthalmic composition comprising a hyperbranched polymer. The ophthalmic compositions may also comprise carbonic anhydrase inhibitors, wherein the hyperbranched polymer increases the aqueous solubility of the carbonic anhydrase inhibitor, and increases corneal permeation of the active agent. The ophthalmic compositions may also comprise non-ionic surfactants, such as polysorbate, hydroxypropyl methyl cellulose or hydroxyethyl cellulose, and beta-blockers, such as carteolol, levobunolol, betaxolol, metipranolol, timolol or propranolol. | 11-10-2011 |
20110275618 | NOVEL LOW CONCENTRATION MELOXICAM TABLETS - The invention relates to a solid tablet that is directly-compressed of powder, comprising meloxicam and one or more excipients which are homogenously dispersed within the tablet that can be broken into two, three or four units with each unit containing equal amounts of the active ingredient, meloxicam. | 11-10-2011 |
20110319399 | EXTERNAL PREPARATION CONTAINING ANALGESIC/ANTI-INFLAMMATORY AGENT - An external preparation containing the following components (A) and (B):
| 12-29-2011 |
20120035162 | PROCESS FOR PREPARATION OF HIGH-PURITY MELOXICAM AND MELOXICAM POTASSIUM SALT - The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium salt monohydrate is produced. Said salt is subsequently treated with mineral or organic acid to yield high-purity meloxicam. | 02-09-2012 |
20120129845 | Inhibitors of Bruton's Tyrosine Kinase - This application discloses 5-phenyl-1H-pyridin-2-one and 6-phenyl-2H-pyridazin-3-one derivatives according to generic Formulae I-IV: | 05-24-2012 |
20120149692 | In Vivo Studies of Crystalline Forms of Meloxicam - The invention is directed to novel crystalline forms of meloxicam. These novel crystalline forms of meloxicam have improved bioavailability, an enhanced rate of dissolution and shorter time to C | 06-14-2012 |
20120165323 | METHOD FOR IMPROVING THE DISSOLUTION PROFILE OF A BIOLOGICALLY ACTIVE MATERIAL - The present invention relates to a method for improving the dissolution profile of a biologically active material comprising the steps of dry milling a solid biologically active material and a millable grinding matrix in a mill comprising a plurality of milling bodies, for a time period sufficient to produce particles of the biologically active material dispersed in an at least partially milled grinding material. | 06-28-2012 |
20120245156 | ORAL LYOPHILIZED COMPOSITIONS - The present invention relates to a method for preparing an oral lyophilizate composition comprising:
| 09-27-2012 |
20120252795 | ORAL LYSOPHILISATES CONTAINING PVP/VA - The present invention relates to novel oral pharmaceutical compositions in lyophilized form, in which the dissolution and the bioavailability of the active ingredient that they contain are improved. The compositions according to the invention comprise in particular a polyvinyl acetate/polyvinylpyrrolidone copolymer. The oral lyophilisates according to the invention are particularly suitable for the production of medicaments based on active ingredients which have low solubility or very low solubility in water or which are virtually insoluble in water. | 10-04-2012 |
20120283252 | PROCESS FOR PREPARING PHARMACEUTICAL OPHTHALMIC COMPOSITIONS - Pharmaceutical ophthalmic compositions comprising active ingredient(s) such as carbonic anhydrase inhibitor (CAI) or combinations and processes for making such compositions and the use of these compositions in patient populations including pediatric populations. A process for preparing an ophthalmic composition comprising a carbonic anhydrase inhibitor, which comprises a) preparing a slurry comprising a carbonic anhydrase inhibitor and a surfactant; b) preparing a polymer slurry comprising a polymer and water; c) preparing a solution comprising tonicity and preservative agents; d) mixing the polymer slurry of step b and the solution of step c, to form a vehicle concentrate and adjusting pH; e) adding the slurry of step a, to the vehicle concentrate of step d and mixing to homogenize; f) autoclaving the mixture of step e; g) sizing the mixture of step f, under aseptic condition. | 11-08-2012 |
20120309749 | Piroxicam-Containing Transdermally Absorbable Preparation - An adhesive patch is provided in which piroxicam is formulated as a non-steroidal anti-inflammatory analgesic. In particular, provided is a piroxicam-containing transdermally absorbable adhesive patch in which an absorption promoter to piroxicam is formulated to achieve high anti-inflammatory and analgesic effects without inhibiting releasing of these drugs. The piroxicam-containing transdermally absorbable adhesive patch contains piroxicam as a medicinal component and oxybuprocaine or a pharmaceutically acceptable salt thereof as an absorption promoter. In the piroxicam-containing transdermally absorbable adhesive patch, the content of piroxicam is from 0.1% to 5% by weight to the total weight of a drug-containing plaster and the content of oxybuprocaine or the pharmaceutically acceptable salt thereof is from 1% to 30% by weight to the total weight of the drug-containing plaster. | 12-06-2012 |
20130005714 | Water-Soluble Meloxicam Granules - Water soluble meloxicam granules comprising:
| 01-03-2013 |
20130012502 | Pharmaceutical or Veterinary Antiviral Compositions - Pharmaceutical or veterinary compositions to prevent or treat viral infections, in particular to prevent or treat influenza A, B and C virus infections. | 01-10-2013 |
20130035330 | USE OF MELOXICAM FOR THE LONG-TERM TREATMENT OF MUSCULOSKELETAL DISORDERS IN CATS - The invention is directed to the use of a formulation comprising meloxicam or a pharmacologically acceptable meloxicam salt of an organic or inorganic base thereof for the long-term treatment of musculoskeletal disorders in cats. No negative effects on renal function occur following a treatment from 10 to 20 months or more. | 02-07-2013 |
20130053374 | OPHTHALMIC COMPOSITION - The present invention provides an ophthalmic composition comprising a hyperbranched polyester. The ophthalmic compositions may also comprise carbonic anhydrase inhibitors, wherein the hyperbranched polyester increases the aqueous solubility of the carbonic anhydrase inhibitor, and increases corneal permeation of the active agent. The ophthalmic compositions may also comprise non-ionic surfactants, such as PEG, Polysorbate, HPMC or HEC, and beta-blockers, such as Carteolol, Levobunolol, Betaxolol, Metipranolol, Timolol or Propranolol. The concentration of the hyperbranched polyester in the ophthalmic formulation should be less than or equal to 4% (w/v) in order to avoid any cytotoxic effects on human corneal cells and thus the eye irritation. | 02-28-2013 |
20130059842 | MANUFACTURING OF QUICK RELEASE PHARMACEUTICAL COMPOSITONS OF WATER INSOLUBLE DRUGS AND PHARMACEUTICAL COMPOSITIONS OBTAINED BY THE PROCESS OF THE INVENTION - It has been found that pharmaceutical compositions comprising water insoluble drugs can be manufactured and formulated in a manner ensuring fast dissolution in gastric fluid. Advantageously, the manufacturing process provides a significantly improved stability, thus resulting in compositions that may have a longer shelf life than conventionally formulated and processed drugs. | 03-07-2013 |
20130065888 | OPHTHALMIC FORMULATIONS AND PROCESSES FOR THEIR PREPARATION - The invention relates to a process for preparing ophthalmic formulations and to formulations containing a suspension of an ophthalmic drug in an aqueous vehicle. The invention further relates to the production of stable ophthalmic formulations that have a minimal propensity to form drug aggregates. | 03-14-2013 |
20130123245 | METHODS FOR ALLEVIATING CHRONIC PAIN AND IMPROVING PERFORMANCE OF CATTLE UNDERGOING DEHORNING OR CASTRATION - Methods of improving performance, increasing weight gain, and decreasing incidence of disease in ruminant and pre-ruminant animals, such as cattle, after undergoing painful processing procedures, such as castration and dehorning, are provided. Veterinary formulations for use in methods of the invention are also provided. The formulations comprise a compound selected from the group consisting of meloxicam, gabapentin, the pharmaceutically acceptable salts thereof, and combinations thereof. Methods of treating pathological pain in cattle are also provided. | 05-16-2013 |
20130165429 | COMPOSITION AND METHOD FOR COMPOUNDED THERAPY - The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously; may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients; and may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, other active ingredients, and DMSO or Sterile Water for Irrigation. In another aspect, the present embodiments relate to methods of compounding medications and transdermal creams or gels. | 06-27-2013 |
20130165430 | COMPOSITION AND METHOD FOR COMPOUNDED THERAPY - The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients. For instance, the transdermal cream may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, and/or other active ingredients. In another aspect, the present embodiments relate to methods of compounding medications and transdermal creams or gels. | 06-27-2013 |
20130178467 | HIGHLY CONCENTRATED STABLE MELOXICAM SOLUTIONS - Aqueous cyclodextrin-free solution of meloxicam for administration by oral or parenteral route, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients, the content of dissolved meloxicam salt being more than 10 mg/mL. The formulation according to the invention has a shelf-life of up to 24 months or more. | 07-11-2013 |
20130190301 | PIROXICAM FOR PROPHYLACTICALLY AND THERAPEUTICALLY TREATING HERPES INFECTIONS - The invention relates to an agent for the prophylactic and therapeutic treatment of virus infections, said agent containing piroxicam in a carrier substance. | 07-25-2013 |
20130203742 | VALACICLOVIR AND MELOXICAM COMBINATION THERAPY FOR FUNCTIONAL SOMATIC SYNDROMES - The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound valaciclovir and a therapeutically-effective amount of the COX-2 inhibitor meloxicam. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of valaciclovir and meloxicam. | 08-08-2013 |
20130203743 | FAMCICLOVIR AND MELOXICAM COMBINATION THERAPY FOR FUNCTIONAL SOMATIC SYNDROMES - The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound famciclovir and a therapeutically-effective amount of the COX-2 inhibitor meloxicam. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of famciclovir and meloxicam. | 08-08-2013 |
20130203744 | ACICLOVIR AND MELOXICAM COMBINATION THERAPY FOR FUNCTIONAL SOMATIC SYNDROMES - The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound aciclovir and a therapeutically-effective amount of the COX-2 inhibitor meloxicam. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of aciclovir and meloxicam. | 08-08-2013 |
20130296309 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS - The present invention provides a compound of formula I; | 11-07-2013 |
20130310371 | Pharmaceutical composition comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexa- ne-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam - The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient, which is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam, droxicam and the physiologically acceptable salts thereof. | 11-21-2013 |
20130310372 | PHARMACEUTICAL TRANSDERMAL COMPOSITIONS AND METHOD FOR TREATING INFLAMMATION IN CATTLE - Novel transdermal preparations combining a non-steroidal anti-inflammatory drug (NSAID) selected from groups such as oxicams (for example, meloxicam), propionic acids (for example, ketoprofen) and anthranilic acids (for example, tolfenamic acid), are disclosed. Methods for using and administering such preparation in the treatment of inflammatory conditions in bovines are also disclosed. | 11-21-2013 |
20130317013 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF - This invention relates to potent selective agonists of the EP | 11-28-2013 |
20130338153 | 8-(2'-HETEROCYCYL)PYRIDO[2.3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS - Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders. | 12-19-2013 |
20140024642 | OPHTHALMIC FORMULATION AND METHOD FOR AMELIORATING PRESBYOPIA - An ophthalmic formulation having an effective amount of a parasympathomimetic agent comprising pilocarpine, or a pharmaceutically acceptable salt thereof, and one or more α1 adrenergic agonists or antagonists is disclosed. The ophthalmic formulation may enable treatment of conditions adversely affecting the visual acuity of a patient, including presbyopia. A method of using the disclosed ophthalmic formulation to treat or ameliorate symptoms of presbyopia is also disclosed. | 01-23-2014 |
20140066440 | Highly Concentrated Stable Meloxicam Solutions for Needleless Injection - A method for treating pain, inflammation, fever and respiratory complaints in mammals comprising administering by needleless injection to a mammal in need of such treatment an aqueous cyclodextrin-free solution of meloxicam containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base. | 03-06-2014 |
20140080818 | TWO-COMPONENT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PAIN - The present invention is directed to a pharmaceutical composition that includes a combination of about 2-5 milligrams of a non-steroidal anti-inflammatory drug and from about 2-30 milligrams of an opioid analgesic in a single pharmaceutical dosage unit that can provide effective chronic pain management with the added benefit of reduced side effects such as withdrawal and gastrointestinal disorders. The non-steroidal anti-inflammatory drug may be piroxicam and the opioid analgesic may be buprenorphine. The present invention also provides for a method of managing pain in a patient that includes administering the pharmaceutical composition previously described. The pharmaceutical composition previously described may be administered in a single or multiple dosage regimens. | 03-20-2014 |
20140113893 | Highly Concentrated Stable Meloxicam Solutions for Needleless Injection - An aqueous cyclodextrin-free solution of meloxicam suitable is provided for administration by needleless injection, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients. | 04-24-2014 |
20140148447 | AGENT FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF HERPES INFECTIONS - The invention relates to an agent for the prophylactic and therapeutic treatment of virus infections, said agent containing piroxicam in a carrier substance. | 05-29-2014 |
20140194413 | INHIBITORS OF BRUTON'S TYROSINE KINASE - This application discloses 5-phenyl-1H-pyridin-2-one and 6-phenyl-2H-pyridazin-3-one derivatives according to generic Formulae I-IV: | 07-10-2014 |
20140200211 | COMPOSITIONS AND METHODS FOR TREATING PRESBYOPIA, MILD HYPEROPIA, AND IRREGULAR ASTIGMATISM - The present invention is directed to compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism. The compositions include a cholinergic agent, such as a muscarinic acetylcholine receptor M | 07-17-2014 |
20140275046 | COMPOSITIONS OF A POLYORTHOESTER AND AN APROTIC SOLVENT - Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release. | 09-18-2014 |
20150011538 | VALACICLOVIR AND MELOXICAM COMBINATION THERAPY FOR FUNCTIONAL SOMATIC SYNDROMES - The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound valaciclovir and a therapeutically-effective amount of the COX-2 inhibitor meloxicam. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of valaciclovir and meloxicam. | 01-08-2015 |
20150051198 | Highly Concentrated Stable Meloxicam Solutions for Needleless Injection - An aqueous cyclodextrin-free solution of meloxicam suitable is provided for administration by needleless injection, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients. | 02-19-2015 |
20150065493 | PROCESS FOR PREPARING STERILE BRINZOLAMIDE - Process of preparing sterile brinzolamide using ethylene-oxide gas sterilisation, sterile brinzolamide obtainable by said process and pharmaceutical compositions comprising said sterile brinzolamide. | 03-05-2015 |
20150080385 | OPHTHALMIC PHARMACEUTICAL COMPOSITION CONTAINING A CARBONIC ANHYDRASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF - The present invention relates to a stable pharmaceutical formulation for topical administration containing a therapeutically effective quantity of Brinzolamide or ophthalmologic acceptable salts thereof and an effective quantity of a surfactant such as poloxamer, to be used for the treatment of ocular hypertension and glaucoma. | 03-19-2015 |
20150111881 | ACYCLOVIR AND MELOXICAM COMBINATION THERAPY FOR FUNCTIONAL SOMATIC SYNDROMES - The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound acyclovir and a therapeutically-effective amount of the COX-2 inhibitor meloxicam. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of acyclovir and meloxicam. | 04-23-2015 |
20150119386 | PROCESS FOR PREPARING OPTHALMIC SUSPENSION OF BRINZOLAMIDE - The present invention relates to a process for preparing sterile ophthalmic suspension of carbonic anhydrase inhibitor. More particularly, the present invention relates to a process for preparing sterile ophthalmic suspension of brinzolamide. | 04-30-2015 |
20150141412 | PRODUCTION OF STERILE ACTIVE PHARMACEUTICAL INGREDIENTS - The invention refers to a process for preparing sterile active pharmaceutical ingredients (APIs) useful in the preparation of sterile product for ophthalmic use. The process comprises the gamma-ray sterilization treatment of the APIs powder in a protective atmosphere. | 05-21-2015 |
20150297609 | STERILE OPHTHALMIC PHARMACEUTICAL SUSPENSIONS - An aqueous suspension of a carbonic anhydrase inhibitor such as brinzolamide as well as methods of preparation thereof, are disclosed. The suspension comprises an organic polar solvent such as dimethyl sulfoxide and/or a non-aromatic non-ionic polyethoxylated surfactant such as polyethoxylated castor oil and/or or polysorbate 80. Methods include precipitating brinzolamide from the heated composition. Methods also include sonication of the suspension to reduce brinzolamide particle size. | 10-22-2015 |
20150320760 | VALACICLOVIR AND MELOXICAM COMBINATION THERAPY FOR FUNCTIONAL SOMATIC SYNDROMES - The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound valaciclovir and a therapeutically-effective amount of the COX-2 inhibitor meloxicam. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of valaciclovir and meloxicam. | 11-12-2015 |
20150336974 | Cyclic Sulfonamides as Sodium Channel Blockers - The present disclosure provides cyclic sulfonamides of Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R | 11-26-2015 |
20160022822 | MELOXICAM EYE DROPS AND PREPARATION METHOD AND USE THEREOF - Disclosed are meloxicam eye drops and the preparation method and use thereof. The eye drops contain active ingredient meloxicam or a pharmaceutically acceptable salt thereof, a solubilizer, a stabilizer, a pH adjusting agent, an antimicrobial agent and an osmotic pressure adjusting agent, wherein the solubilizer is one of hydroxypropyl-β-cyclodextrin, sulfobutylether-β-cyclodextrin, and β-cyclodextrin or a mixture thereof, and the stabilizer is one of polymer povidone, sodium hyaluronate, and hypromellose or a mixture thereof. | 01-28-2016 |
20160102086 | NOVEL FORMULATION OF MELOXICAM - The present invention relates to methods for producing particles of meloxicam using dry milling processes as well as compositions comprising meloxicam, medicaments produced using meloxicam in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of meloxicam administered by way of said medicaments. | 04-14-2016 |
20160102105 | BACE1 INHIBITORS - The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease. | 04-14-2016 |
20160375140 | LONG-ACTING POLYMERIC DELIVERY SYSTEMS - Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural). | 12-29-2016 |
20190142942 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | 05-16-2019 |
20190142943 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | 05-16-2019 |